Cyclooxygenase-2 Selective Nonsteroidal Anti-Inflammatory Drugs and the Risk of Ischemic Stroke
作者： Frank Andersohn , René Schade , Samy Suissa , Edeltraut Garbe
DOI: 10.1161/01.STR.0000226642.55207.94
关键词:
摘要: Background and Purpose— Several randomized trials a large number of epidemiological studies have provided evidence an increased risk acute myocardial infarction associated with the use cyclooxygenase (COX)-2 selective nonsteroidal anti-inflammatory drugs (NSAIDs). Few data are available concerning ischemic stroke COX-2 inhibitors. Methods— We performed nested case-control study in cohort 469 674 patients registered within UK General Practice Research Database (GPRD), who had at least 1 prescription NSAID between June 1, 2000 October 31, 2004. A total 3094 cases were identified 11 859 controls matched on age, sex, year entry general practice. Odds ratios (ORs) NSAIDs calculated by conditional logistic regression. Results— Current rofecoxib (OR=1.71; 95% CI, 1.33 to 2.18), etoricoxib (OR=2.38; 1.10 5.13), but not ...
sci-hub.se 参考文章(17)
Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. JAMA Internal Medicine. ,vol. 165, pp. 490- 496 ,(2005) , 10.1001/ARCHINTE.165.5.IOI50013
Elisabeth Ott, Nancy A Nussmeier, Peter C Duke, Robert O Feneck, R Peter Alston, Michael C Snabes, Richard C Hubbard, Ping H Hsu, Lawrence J Saidman, Dennis T Mangano, Multicenter Study of Perioperative Ischemia (McSPI) Research Group, None, Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery The Journal of Thoracic and Cardiovascular Surgery. ,vol. 125, pp. 1481- 1492 ,(2003) , 10.1016/S0022-5223(03)00125-9
G. C. Hall, M. M. Brown, J. Mo, K. D. MacRae, Triptans in migraine: The risks of stroke, cardiovascular disease, and death in practice Neurology. ,vol. 62, pp. 563- 568 ,(2004) , 10.1212/01.WNL.0000110312.36809.7F
Garret A. FitzGerald, Coxibs and Cardiovascular Disease The New England Journal of Medicine. ,vol. 351, pp. 1709- 1711 ,(2004) , 10.1056/NEJMP048288
Lynda Wilton, Saad AW Shakir, Rachna Kasliwal, Deborah Layton, Scott Harris, A Comparison of Reported Gastrointestinal and Thromboembolic Events Between Rofecoxib and Celecoxib Using Observational Data Drug Safety. ,vol. 28, pp. 803- 816 ,(2005) , 10.2165/00002018-200528090-00005
Andrew Whelton, William B White, Alfonso E Bello, Joseph A Puma, John G Fort, SUCCESS-VII Investigators, Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis American Journal of Cardiology. ,vol. 90, pp. 959- 963 ,(2002) , 10.1016/S0002-9149(02)02661-9
Susan S. Jick, James A. Kaye, Catherine Vasilakis-Scaramozza, Luis A. García Rodríguez, Ana Ruigómez, Christoph R. Meier, Raymond G. Schlienger, Corri Black, Hershel Jick, Validity of the general practice research database. Pharmacotherapy. ,vol. 23, pp. 686- 689 ,(2003) , 10.1592/PHCO.23.5.686.32205
Nancy A. Nussmeier, Andrew A. Whelton, Mark T. Brown, Richard M. Langford, Andreas Hoeft, Joel L. Parlow, Steven W. Boyce, Kenneth M. Verburg, Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery The New England Journal of Medicine. ,vol. 352, pp. 1081- 1091 ,(2005) , 10.1056/NEJMOA050330
D. Layton, Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data. Rheumatology. ,vol. 42, pp. 1354- 1364 ,(2003) , 10.1093/RHEUMATOLOGY/KEG401
D Layton, E Heeley, K Hughes, SAW Shakir, Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription‐event monitoring data Rheumatology. ,vol. 42, pp. 622- 631 ,(2003) , 10.1093/RHEUMATOLOGY/KEG141